Company profile
Thermo Fisher Scientific Inc.
NYSE: TMO · Healthcare · Medical - Diagnostics & Research
#17 of 1,417 Healthcare companies by revenue47th-percentile growth
EA Score
86AFH 86DQ 96GM 57SS 100
v0.1 · 65/100 weight · provisional
↑ market scale, workforce scale · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$45.2B
Rev growth YoY (TTM)
+5.4%
Net income (FY)
$6.7B
Employees
125,000
as of 2026-08-04
Market cap
$213.3B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$44.6B$44.6B2025
Net income$6.7B$6.7B2025
Operating income$7.7B$7.7B2025
Total assets$110.3B$110.3B2025
Equity$53.4B$53.4B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Consumables42%
Service42%
Instruments16%
By geography
UNITED STATES52%
Europe27%
Asia Pacific18%
All Other Countries4%
The read
What is Thermo Fisher Scientific Inc.’s revenue?
Thermo Fisher Scientific Inc. booked $44.6B in FY2025 revenue, growing 3.9% year over year — about the middle of the pack among Healthcare companies we track, at a 15.0% net margin.
Peers · Healthcare
AbbVie Inc.81B+Bristol-Myers Squibb Company85AMolina Healthcare, Inc.83B+Abbott Laboratories87AAmgen Inc.88AMedtronic plc84B+Neighbors
Middlesex →Key facts
CEOMarc N. Casper
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersWaltham, MA
ExchangeNYSE: TMO
Employees125,000
IPO date1980-03-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.